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Abstract
Background: Interleukin-6 (IL-6) contributes to numerous inflammatory, metabolic, and physiologic pathways of disease.
We evaluated four IL-6 immunoassays in order to identify a reliable assay for studies of metabolic and physical function.
Serial plasma samples from intravenous glucose tolerance tests (IVGTTs), with expected rises in IL-6 concentrations, were
used to test the face validity of the various assays.
Methods and Findings: IVGTTs, administered to 14 subjects, were performed with a single infusion of glucose (0.3 g/kg body
mass) at time zero, a single infusion of insulin (0.025 U/kg body mass) at 20 minutes, and frequent blood collection from time
zero to 180 minutes for subsequent Il-6 measurement.The performance metrics of four IL-6detection methods were compared:
Meso Scale Discovery immunoassay (MSD), an Invitrogen Luminex bead-based multiplex panel (LX), an Invitrogen Ultrasensitive
Luminex bead-based singleplex assay (ULX), and R&DHigh SensitivityELISA (R&D). IL-6concentrations measured withMSD, R&D
and ULX correlated with each other (Pearson Correlation Coefficients r=0.47–0.94, p,0.0001) but only ULX correlated (r=0.31,
p=0.0027)withInvitrogenLuminex.MSD,R&D,andULX,butnotLX,detectedincreasesinIL-6inresponsetoglucose.Allplasma
samples were measurable by MSD, while 35%, 1%, and 4.3% of samples were out of rangewhen measured by LX, ULX, and R&D,
respectively.BasedonrepresentativedatafromtheMSDassay,baselineplasmaIL-6(0.9060.48 pg/mL) increased significantly as
expected by 90 minutes (1.2960.59 pg/mL, p=0.049), and continued rising through 3 hours (4.2563.67 pg/mL, p=0.0048).
Conclusion: This study established the face validity of IL-6 measurement by MSD, R&D, and ULX but not LX, and the
superiority of MSD with respect to dynamic range. Plasma IL-6 concentrations increase in response to glucose and insulin,
consistent with both an early glucose-dependent response (detectable at 1–2 hours) and a late insulin-dependent response
(detectable after 2 hours).
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Introduction
Interleukin-6 (IL-6) is a cytokine that is released from a
multitude of sites under a wide range of conditions. IL-6 secreted
by immune cells, adipocytes and endothelial cells plays a well
known role in the chronic low-grade inflammation characteristic
of obesity [1,2], diabetes and cardiovascular disease [3], as well as
the acute immunological crises of infection and sepsis [4].
However, more recent studies have challenged the notion that
the actions of IL-6 are either entirely immunological or wholly
detrimental. IL-6 is released from contracting skeletal muscle
before and after exercise, including moderate ‘‘non-damaging’’
exercise recommended by health professionals [5]. Furthermore,
increases in plasma IL-6 concentrations directly stimulate both
glucose [6] and lipid metabolism [7]. The additional finding that
plasma IL-6 also rises in response to both acute hyperglycemic
clamp and pulse [8], as well as hyperinsulinemia [9] highlights the
potential role of this cytokine in substrate metabolism.
In normal healthy subjects free of inflammation, IL-6 concen-
trations are typically quite low, in the range of 0.2–7.8 pg/mL
[10,11] but can exceed concentrations of 1600 pg/mL in sepsis
[12]. More modest increases in IL-6 concentrations are associated
with age [13], hyperglycemia [8] and the physiologic stress of acute
exercise [5]. As IL-6 is detectible in plasma it therefore has the
potential to reflect systemic inflammatory, metabolic, and physio-
logic stimuli. To elucidate the multiple biological pathways in which
IL-6is involved,it is essentialto havethe abilityto precisely quantify
it across a broad dynamic concentration range and to have
confidence in the face validity of the measure, i.e., that it is
measuring what it is purported to measure.
Therefore we designed a study to assess the performance
metrics and face validity of cytokine concentrations generated by
three different IL-6 immunoassays. In designing this study, we
proposed several criteria a priori to judge the performance of each
particular immunoassay. At a minimum, the dynamic range of the
assay needed to be broad enough to measure both the low levels of
IL-6 found in normal healthy individuals as well as the high levels
characteristic of altered homeostasis associated with many disease
or pre-disease conditions, ideally without the need for diluting
samples to bring their values into range. Second, it was particularly
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variability within and between plates, but across different kit lots
produced at different times in order to perform meta-analyses of
data derived from multiple studies over time. Third, it was
important that the values produced by a particular assay fulfill face
validity criteria by showing the ability to detect potentially
biologically relevant changes in plasma IL-6 in response to
appropriate stimuli. This assessment required a sample set in
which IL-6 concentrations would be expected to change in a
predictable way in response to physiologic stimulation. Hypergly-
cemia [8] and hyperinsulinemia [9] have each been shown to raise
plasma IL-6 levels, although with different response times.
Therefore we chose to evaluate IL-6 in a set of serial samples
obtained from healthy, but obese, middle-aged subjects during a
frequently sampled intravenous glucose tolerance test (IVGTT).
We hypothesized that single infusions of glucose and insulin would
result in a measureable elevation in plasma IL-6 concentrations.
Additionally, our goal was to identify a method for IL-6
quantification that met all three pre-specified assessment criteria.
Methods
Participants and Ethics Statement
On the basis of availability of sufficient volumes, samples from a
total of 14 subjects were selected from the control arm (no exercise
intervention) of the Studies Targeting Risk Reduction Interven-
tions through Defined Exercise (STRRIDE) [14]. The purpose of
STRRIDE was to assess the effect of the volume and intensity of
exercise training on insulin sensitivity in a population of
overweight, sedentary, non-diabetic, middle-aged adults. Informed
written consent was obtained from all subjects, and all procedures
were approved by the Institutional Review Board of Duke
University Medical Center.
Intravenous Glucose Tolerance Testing
The subjects underwent an IVGTT during which EDTA
plasma was collected and stored at 280uC [14]. Briefly, glucose
(50%) was injected into a catheter placed in the antecubital vein at
a dose of 0.3 g/kg body weight, and insulin (0.025 U/kg body
weight) was injected at minute 20. Blood samples were obtained
frequently (T=0, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 19, 22, 25, 30, 40,
50, 60, 70, 80, 90, 100, 120, 140, 160, and 180 minutes),
centrifuged, and plasma was frozen at 280uC for later analysis.
Glucose and insulin were measured at all time points while IL-6
was measured at T=0, 2, 6, 14, 19, 25, 30, 40, 60, 90, 120 and
180 minutes. A total of 162 samples were assayed using MSD,
while limited plasma reduced the sample number to163 for R&D,
161 for Luminex, and 131 for HS Luminex.
Analyte Measurement and Assay Validation
Plasma insulin was determined by immunoassay and glucose
was determined with an oxidation reaction as previously described
[15]. Plasma was assayed for IL-6 by four methods according to
the manufacturers’ protocols: 1) MSD - IL-6 Ultra Sensitive Assay
(Meso Scale Discovery, Gaithersburg, Maryland), 2) R&D - High
Sensitivity IL-6 ELISA (R&D Systems, Minneapolis, Minnesota),
3) ULX – IL-6 Ultrasensitive Singleplex Bead Kit (Invitrogen
Corporation, Carlsbad, California), and 4) LX - as part of a
Luminex Custom Multi-plex panel consisting of IL-6, and 12 other
cytokines and chemokines: brain-derived neurotrophic factor
(BDNF), granulocyte colony stimulating factor (GCSF), interleukin
1 receptor antagonist (IL-1RA) interleukins 1b, 2, and 8 (IL-1b,
IL-2, IL-8), monocyte chemotactic protein 1 (MCP-1), regulated
upon activation, normal T-cell expressed and secreted (RANTES),
tumor necrosis factor a (TNFa ´), tumor necrosis factor receptors 1
and 2 (TNFR1 and TNFR2), and vascular endothelial growth
factor (VEGF) (Invitrogen Corporation, Carlsbad California). In
addition to IVGTT samples, each manufacturer’s standards were
assayed by each of the other immunoassay methods, with the
exception of measurement of Luminex calibrators by Ultrasensi-
tive Luminex, and vice versa, due to limiting reagents.
Pooled plasma from four healthy subjects served as a control
specimen. For all assays, the mean of the pooled control sample plus
or minus 2SDs was defined as the acceptable precision limits. Any
platesinwhichthecontrol falls outsideof thisrange arerepeated.No
repeat plate analyses were required in this study based on this
criterion. The dynamic range of each assay was defined by the
highest and lowest concentrations of calibrators specified in each kit.
Of note, the pooled control sample was within the manufacturer’s
published dynamic range for each assay (Table 1). The range of
sample measurements was defined by the highest and lowest IL-6
concentrations in IVGTT plasma samples obtained via each
method. Quantifiability, or the percentage of samples that were in
the range of each assay, was defined as the ratio of the number of
samplesyielding concentrationswithinthe assayrange/totalnumber
of samples assayed; samples outside the measureable ranges were
denoted as those that were either above or below the upper or lower
limits of quantification. For purposes of graphical representation
only, samples with IL-6 values above or below the range of detection
weresubstitutedwith valuestwicethe upperlimit ofquantification or
one-half the lower limit of quantification, respectively, as determined
by the highest and lowest concentrations of the standard curve.
Reproducibility was reported as percent coefficient of variation
(%CV), calculated as 100*SD/Mean. Intra-plate variability was
calculated using duplicate measure of manufacturers’ calibrators
and plasma IVGTT samples, based on availability as follows: for
MSD, all calibrator curves and 163 IVGTT samples; for R&D, all
calibrator curves and 162 IVGTT samples; for LX all calibrator
curves (except ULX) and 22 IVGTT samples; and for ULX all
calibrator curves except LX. Inter-plate and inter-lot variability was
assessed using a pooled plasma sample (collected from four
individuals) measured in duplicate on MSD and R&D and
measurement of 100 beads from individual wells on LX and
ULX. Two lots were compared for MSD and LX, three lots were
compared for R&D, while only lot was available for ULX. To assess
responsiveness of IL-6 to IVGTT, serum samples were measured in
duplicate for MSD and R&D (unless sample was limited, as
indicated) and in the case of the bead based assays, LX and ULX, a
minimum of 100 beads were analyzed from individual wells.
Pearson correlation coefficients were calculated using IL-6
measurements from plasma samples. To assess agreement between
assays we performed Bland Altman tests [16] of z score normalized
data where z=(x – m)/s, where x is the raw concentration, and mand
s are the mean and standard deviation of all concentrations for that
assay. This was necessary due to the fact that the units of measure for
LX were much greater than for the other assays. To evaluate
responsiveness to glucose, untransformed IL-6 concentrations at
t=180 minutes were compared to baseline for each subject using the
paired t test. In four subjects (1, 7, 8, and 13) baseline sample was
unavailable for assay by ULX, therefore comparisons were made to
sample collected at 2 or 6 minutes. Statistical analysis was performed
using GraphPad Prism, with significance defined as p,0.05.
Results
To assess the responsiveness of IL-6 to glucose and insulin, as
well as to compare the performance parameters of three IL-6
detection methods, we used IVGTT plasma samples from 14
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(21%), the mean age was 50.4 yr (range 40–61), and mean BMI
was 29.1 kgNm
22 (range 26.7–32.2). Numerous performance
metrics were compared among the four immunoassays, as
summarized in Table 1. Sample volumes required for assays
varied from 25 ml (MSD) to 50 ml (LX and ULX) to 100 ml (R&D).
For all IVGTT plasma samples, LX returned values that were
significantly higher than those reported by the other three assays,
while in most cases MSD returned the lowest values (Figures
S1,S2,S3,S4,S5,S6,S7,S8,S9,S10,S11,S12,S13,S14). This rank or-
der was also reflected in the overall means (pg/mL) of the IVGTT
samples: LX (53.1), ULX (2.07), R&D (1.68), and MSD (1.08)
(Table 1). IL-6 concentrations (mean, SD in pg/ml) of control
samples pooled from the serum of four healthy subjects were
reported highest by LX (21.9, 5.3) followed by R&D (0.63, 0.1),
ULX (0.27, 0.03) and MSD (0.26, 0.05).
Reproducibility (both within plates and between plates and lots)
was similar and acceptable for both MSD and R&D, but lower for
LX and ULX. MSD, R&D, and ULX (but not LX) consistently
detected changes in IL-6 concentration upon stimulation by glucose
administered during the IVGTT (Table 1 and Figures S1,S2,S3,S4,
S5,S6,S7,S8,S9,S10,S11,S12,S13,S14). Although similar in many
respects, a notable difference between these assays was the dynamic
range. While both R&D and ULX were designed to detect the very
low levels of IL-6 typically found in healthy individuals, both assays
failed to measure one low value (0.6% and 1% respectively).
Additionally, R&D was constrained by an upper limit of 10 mg/ml,
yielding out of range (too high) values for 6 (3.7%) samples.
Although the upper range oftheLX assay was presumablysufficient
to capture these high values, it was constrained by a lower limit of
detection of 9.47 pg/ml, thus failing to measure 35% of the samples
assayed here. Only MSD detected IL-6 in all samples measured,
and had the capacity to yield results on the first determination for
samples with very high concentrations thus minimizing the need for
sample dilution and reassay. Obtaining high-end measurements
with R&D and ULX could potentially require dilution of samples,
with the consequences of both higher costs (due to need for multiple
repeat measurements)and higher technical variability in the studies.
Calibrators (IL-6 standards) from each manufacturer were
tested on each of the other assays (Figure 1) and produced
generally parallel standard curves. However, there was notable
variability in the measured signals between different calibrators
that were expected to contain similar concentrations of IL-6. This
variability was generally least at low IL-6 concentrations and
greater at higher concentrations. Variability between calibrators
was lowest for R&D compared to the three other immunoassays,
and highest for ULX. Additionally, the four assays displayed
different rank orders of standard curves: MSD (MSD.R&D.
ULX.LX); R&D (LX.MSD.R&D.ULX), LX (MSD.
R&D.LX), and ULX (ULX.MSD.R&D).
Correlations of IL-6 concentrations (Table 2) between MSD
and both R&D and ULX assays were strongest (Pearson
correlation coefficient r=0.94, p,0.0001; r=0.90, p,0.0001,
respectively), and weaker between R&D and ULX (r=0.47,
p,0.0001). LX correlated poorly with ULX (r=0.31. p=0.0027)
and not at all with MSD and R&D (r=0.15, p=0.13; r=20.17,
p=0.097). While Bland Altman plots (displaying the means vs. the
differences of sample measurements) are the standard method of
Table 1. Performance metrics of four IL-6 immunoassays.
Assay Characteristic
MesoScale
Discovery (MSD)
Invitrogen
Multiplex Bead
Panel (LX)
Invitrogen
Ultrasensitive
Singleplex (ULX)
R&D HS ELISA
(R&D)
Volume of Sample Required 25 ml5 0 ml5 0 ml1 0 0 ml
Dynamic Range of Assay (pg/mL) Minimum 0.163 9.47 0.182 0.156
Maximum 2500 6900 133 10
Concentration of Control Samples
(pg/mL)
Mean (SD) 0.26 (0.05) 21.9 (5.3) 0.27 (0.03) 0.63 (0.01)
Range of Sample Measurements
(pg/mL0
Minimum 0.3 9.47 0.43 0.31
Maximum 13.7 384.9 23.99 8.89
Mean 1.28 56.98 2.52 1.52
Median 0.79 24.99 1.47 1.28
Quantifiability of Samples % Samples in Assay Range 100% (163/163) 65% (104/161) 99% (130/131) 95.6% (155/162)
% Samples ,LLOQ 0 35% (57/161) 1% (1/131) 0.6% (1.162)
% Samples .ULOQ 0 0 0 3.7% (6/162)
Reproducibility (%CV) Intra-Plate Variability 4.8 5.6 18.3 6.3
Inter-Plate Variability 15.7 24.3 28.1 17.9
Inter-Lot Variability 19.9 37.2 NA 16.4
Detection of Biological Response
(Increase in IL-6 with Hyperglycemia
Mean Difference (Stimulated –
Baseline) (pg/mL)
3.35 3.42 5.02 8.32
95% Confidence Interval 1.21, 5.48 5.9, 12.8 1.5, 8.5 3.54, 13.11
Significance of Difference
(Stimulated – Baseline)
P=0.0048 P=0.4445 P=0.0088 P=0.0024
%CV=100*SD/Mean; LLOQ=lower limit of quantification; ULOQ=upper limit of quantification; NA not analyzed. Volume was limiting in some samples permitting the
following numbers of independent analyses: MSD n=163, R&D n=162, LX n=161, and ULX n=131. Detection of a biological response was determined by paired t test
of IL-6 concentrations measured at baseline and at 180 minutes.
doi:10.1371/journal.pone.0030659.t001
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values returned by LX compared with the other three assays
necessitated comparison across assays using z scores that
normalize each set of values and express them as standard
deviations from the mean. Bland Altman plots revealed the highest
agreement (narrower limits of agreement) between MSD, R&D,
and ULX, and essentially no agreement between LX and any of
the other assays (Figure 2).
Figure 1. IL-6 protein calibrators of four immunoassays. IL-6 calibrators (standards) from MesoScale Discovery (N MSD), Invitrogen Luminex (&
LX), and R&D High Sensitivity ELISA (m R&D), and Invitrogen Ultrasensitive Luminex (6ULX) were assayed using each of four manufacturers’ kit
components. Values represent duplicate measurement for MSD and R&D, and duplicate measures of at least 100 beads each for Luminex and
Ultrasensitive Luminex.
doi:10.1371/journal.pone.0030659.g001
Critical Appraisal of Four IL-6 Immunoassays
PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e30659To assessthe responsivenessofthe IL-6immunoassaystochanges
in IL-6, we measured IL-6 in serial plasma samples derived from
IVGTTs. We hypothesized that an assay capable of detecting the
modest changes in IL-6 concentrations would meet criteria for
biological plausibility and face validity; namely that the assay would
be capable of detecting biologically relevant variation in IL-6
concentrations under a wide range of conditions and would be
measuring what it purports to measure. Over the course of the
180 minute IVGTT, IL-6 increased significantly compared to
baseline, as detected by MSD, R&D, ULX, but not LX. These
increases in IL-6 were discernible when the IVGTT time course of
each individual subject was plotted (Figures S1,S2,S3,S4,S5,S6,S7,
S8,S9,S10,S11,S12,S13,S14). To further characterize the concen-
trations of IL-6, the timecourse of mean glucose and insulin
concentrations during the course of the IVGTT were plotted
(Figure 3, representative data derived from MSD assay). As
expected, mean glucose rose after glucose infusion peaking three
minutes after the beginning of the IVGTT at a mean (SD)
concentration of 253 (45.8) mg/dL before returning to baseline
within one hour. Insulin, via endogenous release, increased
immediately following glucose infusion, reaching an initial mean
peak (SD) concentration of 72.3 (38.0) pmol/L at 4 minutes, and a
subsequent peakmean (SD) concentrationof270.4(99.5)pmol/Lat
22 minutes following insulin infusion at 20 minutes, then returned
to a concentration equivalent to baseline concentrations by
90 minutes. The mean (SD) IL-6 concentration, 0.90 (0.49) pg/
mL, was equivalent to baseline concentration until 60 minutes after
the start of the IVGTT, became significantly different from baseline
at 90 minutes (1.2960.59 pg/mL, p=0.049) and continued to rise
steadily until 180 minutes (4.2563.67 pg/mL, p=0.0048) when
the IVGTT was terminated. These characteristic changes in IL-6
during an IVGTT confirm the face validity to the MSD
immunoassay and the R&D and ULX assays that showed a similar
pattern of IL-6 change.
Discussion
In this validation study, we sought not only to quantify the
dynamic range and reproducibility of each method, but important-
ly, to establish the face validity of the IL-6 immunoassays through
demonstration of biologically plausible change during the course of
an IVGTT. Based on results of Esposito et al. [8], and the fact that
we used similar glucose pulse conditions, we expected to see
increases in plasma IL-6 levels during the course of an IVGTT
study. MSD, R&D and ULX all detected changes in IL-6
concentrations in response to glucose and insulin, and were
comparable with regard to other assay metrics, with the exception
that MSD had a broader dynamic range than ULX or R&D.
Correlation of concentrations, and agreement as assessed by
modified Bland-Altman tests were strong between the three assays
but weak with LX, suggesting that the three assays are indeed
measuring the same analyte, i.e., IL-6. The variability in standard
curves of different manufacturers (Figure 2), while not extreme, was
nevertheless noteworthy. Some variability in concentrations and the
potential presence of impurities in different formulations, even from
the same manufacturer, are to be expected. Calibrator variation is
likely to be the source of systematic bias in measurements between
different assays, although differences in the recognizing antibodies
may also play a role. These differences are to be expected since
immunoassays are neither capable nor designed to yield absolutely
precise concentrations of analytes and ultimately this variability
could be adjusted with an international standard.
The IL-6 results derived from the IVGTTs suggested two
phases of an IL-6 response that appear to reflect distinct but
coordinated regulation by glucose and insulin. Furthermore, the
extended duration of IL-6 elevation suggests that gene expression,
protein synthesis and release, and clearance may all be involved in
IL-6 regulation by glucose and insulin, demonstrating an
interaction between immunological and metabolic pathways. In
our study, both glucose and insulin were infused intravenously, the
former at the start of the IVGTT and the latter after 20 minutes.
Although the infusion of glucose and insulin in our study were
episodic rather than continuous, and insulin was infused at lower
concentrations than previously tested [9], we nevertheless detected
a significant increase in plasma IL-6 concentrations in response to
both stimuli. IL-6 rose steadily after the first 60 minutes through
the end of the study at 3 hours, correlating temporally with both
glucose and insulin infusion.
These data complement and expand the existing data on IL-6
variation in response to change in glucose homeostasis. In one
previous study [8], hyperglycemic clamp (with inhibition of insulin
release) led to a phasic (rapid rise by one hour, then return to
baseline by three hours) response of IL-6. In contrast, sustained
hyperinsulinemia (with glucose held at fasting levels) led to a slow
and continuous rise in IL-6 beginning after 2–3 hours and
continuing at least 6 hours [9]. It remains to be seen how changes
in glucose tolerance and insulin sensitivity, as impaired by obesity
or ameliorated by exercise, might be reflected in the pattern of IL-
6 response.
As the number and type of molecular assays proliferate, it
becomes increasingly important for research groups to thought-
fully choose and validate the methods by which they generate
biomarker data. Earlier efforts may have dispensed with this step
for the simple reason that only one assay may have been available
for a particular analyte, but years of product development have
increased options as well as the responsibility to deliberately select
a method that optimizes the criteria required of the research
objectives. Regarding the technical aspects of this study, of the
three assay methods, the MSD Ultra Sensitive Immunoassay
proved preferable for quantifying IL-6. The dynamic range
accommodated both the very high and low concentrations,
variability within and between plates and between lots was
sufficiently low, and the assay required only small volumes of
sample.. We experienced problems in measuring IL-6 with the
Invitrogen Luminex assay in the context of a multiplex panel,
Table 2. Pearson Correlations between four IL-6 assays.
MesoScale
Discovery
(MSD)
R&D HS
ELISA
(R&D)
Invitrogen
Multiplex
Bead Panel
(LX)
R&D HS ELISA (R&D) r 0.94
95% CI 0.92–0.96
p ,0.0001
Invitrogen Multiplex
Bead Panel (LX)
r 0.15 20.17
95% CI 20.04–0.339 20.36–0.032
p 0.13 0.097
Invitrogen
Ultrasensitive
Singleplex (ULX)
r 0.90 0.47 0.31
95% CI 0.86–0.93 0.32–0.598 0.11–0.486
p ,0.0001 ,0.0001 0.0027
Pearson correlation coefficient, r; confidence interval, CI.
doi:10.1371/journal.pone.0030659.t002
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between lots), and inconsistent detection of analyte changes in
response to physiologic stimuli. We have had more consistent
results and continue to use Invitrogen Luminex for other analytes.
The Invitrogen Ultrasensitive Luminex provides an acceptable
alternative, although its dynamic range and reproducibility are
more limited than MSD. Perhaps most important, the face validity
of the MSD, R&D, and ULX assays - i.e., that they are actually
Figure 2. Modified Bland-Altman tests comparing four IL-6 immunoassays. IL-6 concentrations. IL-6 concentrations were standardized
by calculating the z score using z=(x–m)/s, where x is the raw concentration, and m and s are the mean and standard deviation of all concentrations
for that assay. The limits of agreement are denoted by hatch marks representing the mean 6 2SD of the differences in measurements. Out of range
values (LX n=57, ULX n=1, R&D n=7, as reported in Table 1) were excluded from these analyses.
doi:10.1371/journal.pone.0030659.g002
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established by both the correlation and agreement between the
three assays) as well as the detection of changes in IL-6
concentrations in response to exogenous glucose and insulin,
representing a biologically relevant stimulus. In conclusion, MSD,
R&D and ULX all provided reliable assays with high face validity
but only MSD, with its broad dynamic range, provided values in
the linear range of the assay in the first determination, thereby
minimizing cost, time expenditure and sample use.
Supporting Information
Figure S1 Plasma IL-6 during frequently sampled
intravenous glucose tolerance test (IVGTT) in subject
1. Plasma concentrations of IL-6 were measured by MesoScale
Discovery (N MSD), R&D High Sensitivity ELISA (& R&D),
Invitrogen Luminex (m LX) and Invitrogen Ultrasensitive
Luminex (6ULX). Due to limited sample volumes, it was not
possible to provide measurements for one time point (180 minutes)
using LX, for one time point (120 minutes) using R&D, and for
two time points (30 and 120 minutes) using ULX.
(TIF)
Figure S2 Plasma IL-6 during frequently sampled
intravenous glucose tolerance test (IVGTT) in subject
2. Plasma concentrations of IL-6 were measured by MesoScale
Discovery (N MSD), R&D High Sensitivity ELISA (& R&D), and
Invitrogen Luminex (m LX) and Invitrogen Ultrasensitive
Luminex (6ULX). No sample was available for measurement at
one time point (14 minutes).
(TIF)
Figure S3 Plasma IL-6 during frequently sampled intra-
venous glucose tolerance test (IVGTT) in subject 3. Plasma
concentrations of IL-6 were measured by MesoScale Discovery (N
MSD), R&D High Sensitivity ELISA (& R&D), and Invitrogen
Luminex (m LX) and Invitrogen Ultrasensitive Luminex (6ULX).
One sample (180 minutes) returned an IL-6 value above the range
of detection (R&D) and was substituted with a value twice the upper
limit of quantification, as determined by the highest concentration
of the standard curve, and denoted by (,). No sample was available
for measurement at one time point (6 minutes).
(TIF)
Figure S4 Plasma IL-6 during frequently sampled intra-
venous glucose tolerance test (IVGTT) in subject 4. Plasma
concentrations of IL-6 were measured by MesoScale Discovery (N
MSD), R&D High Sensitivity ELISA (& R&D), and Invitrogen
Luminex (m LX) and Invitrogen Ultrasensitive Luminex (6ULX).
Due to limited sample volumes, it was not possible to provide
measurements for two time points (6 and 25 minutes) using ULX.
(TIF)
Figure S5 Plasma IL-6 during frequently sampled intra-
venous glucose tolerance test (IVGTT) in subject 5. Plasma
concentrations of IL-6 were measured by MesoScale Discovery (N
MSD), R&D High Sensitivity ELISA (& R&D), and Invitrogen
Luminex (m LX) and Invitrogen Ultrasensitive Luminex (6ULX).
Due to limited sample volumes, it was not possible to provide
measurements for one time point (6 minutes) using LX.
(TIF)
Figure S6 Plasma IL-6 during frequently sampled
intravenous glucose tolerance test (IVGTT) in subject
6. Plasma concentrations of IL-6 were measured by MesoScale
Discovery (N MSD), R&D High Sensitivity ELISA (& R&D), and
Invitrogen Luminex (m LX) and Invitrogen Ultrasensitive
Luminex (6ULX). Due to limited sample volumes, it was not
possible to provide measurements for four time points (2, 14, 30,
and 120 minutes) using ULX.
(TIF)
Figure S7 Plasma IL-6 during frequently sampled
intravenous glucose tolerance test (IVGTT) in subject
7. Plasma concentrations of IL-6 were measured by MesoScale
Figure 3. Plasma glucose, insulin, and IL-6 during frequently sampled intravenous glucose tolerance test (IVGTT). Plasma
concentrations of glucose (&) and insulin (m) (defined by the left Y axis) and IL-6 as measured by Meso Scale Discovery (N) (defined by the right Y axis)
are shown. Glucose (50%, 0.3 g/kg body mass) was infused at time zero, and insulin (0.025 U/kg body mass) was infused at 20 minutes.
Measurements are mean (SD) for n=fourteen subjects; * p value,0.05; ** p value,0.01 as compared to baseline.
doi:10.1371/journal.pone.0030659.g003
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Invitrogen Luminex (m LX) and Invitrogen Ultrasensitive
Luminex (6ULX). Due to limited sample volumes, it was not
possible to provide measurements for six time points (19, 30, 40,
60, 120, and 180 minutes) using ULX.
(TIF)
Figure S8 Plasma IL-6 during frequently sampled
intravenous glucose tolerance test (IVGTT) in subject
8. Plasma concentrations of IL-6 were measured by MesoScale
Discovery (N MSD), R&D High Sensitivity ELISA (& R&D), and
Invitrogen Luminex (m LX) and Invitrogen Ultrasensitive
Luminex (6ULX). Two samples returned IL-6 values above the
range of detection (R&D) and were substituted with values twice
the upper limit of quantification, as determined by the highest
concentration of the standard curve and denoted by (,).
(TIF)
Figure S9 Plasma IL-6 during frequently sampled
intravenous glucose tolerance test (IVGTT) in subject
9. Plasma concentrations of IL-6 were measured by MesoScale
Discovery (N MSD), R&D High Sensitivity ELISA (& R&D), and
Invitrogen Luminex (m LX) and Invitrogen Ultrasensitive
Luminex (6ULX). Due to limited sample volumes, it was not
possible to provide measurements for three time points (14, 19,
and 90 minutes) using ULX.
(TIF)
Figure S10 Plasma IL-6 during frequently sampled
intravenous glucose tolerance test (IVGTT) in subject
10. Plasma concentrations of IL-6 were measured by MesoScale
Discovery (N MSD), R&D High Sensitivity ELISA (& R&D), and
Invitrogen Luminex (m LX) and Invitrogen Ultrasensitive Luminex
(6ULX). One sample (180 minutes) returned an IL-6 value above
the range of detection (R&D) and was substituted with a value twice
the upper limit of quantification, as determined by the highest
concentration of the standard curve, and denoted by (,).
(TIF)
Figure S11 Plasma IL-6 during frequently sampled
intravenous glucose tolerance test (IVGTT) in subject
11. Plasma concentrations of IL-6 were measured by MesoScale
Discovery (N MSD), R&D High Sensitivity ELISA (& R&D), and
Invitrogen Luminex (m LX) and Invitrogen Ultrasensitive
Luminex (6ULX). One sample (180 minutes) returned an IL-6
value above the range of detection (R&D) and was substituted with
a value twice the upper limit of quantification, as determined by
the highest concentration of the standard curve, and denoted by
(,). Due to limited sample volumes, it was not possible to provide
measurements for one time point (14 minutes) using ULX.
(TIF)
Figure S12 Plasma IL-6 during frequently sampled
intravenous glucose tolerance test (IVGTT) in subject
12. Plasma concentrations of IL-6 were measured by MesoScale
Discovery (N MSD), R&D High Sensitivity ELISA (& R&D), and
Invitrogen Luminex (m LX) and Invitrogen Ultrasensitive
Luminex (6ULX).Due to limited sample volumes, it was not
possible to provide measurements for four time points (6, 14, 40,
and 60 minutes) using ULX.
(TIF)
Figure S13 Plasma IL-6 during frequently sampled
intravenous glucose tolerance test (IVGTT) in subject
13. Plasma concentrations of IL-6 were measured by MesoScale
Discovery (N MSD), R&D High Sensitivity ELISA (& R&D), and
Invitrogen Luminex (m LX) and Invitrogen Ultrasensitive
Luminex (6ULX). No sample was available for measurement at
one time point (120 minutes).
(TIF)
Figure S14 Plasma IL-6 during frequently sampled
intravenous glucose tolerance test (IVGTT) in subject
14. Plasma concentrations of IL-6 were measured by MesoScale
Discovery (N MSD), R&D High Sensitivity ELISA (& R&D), and
Invitrogen Luminex (m LX) and Invitrogen Ultrasensitive
Luminex (6ULX). One sample (180 minutes) returned an IL-6
value above the range of detection (R&D) and was substituted with
a value twice the upper limit of quantification, as determined by
the highest concentration of the standard curve, and denoted by
(,). No sample was available for measurement at two time points
(19 and 60 minutes).
(TIF)
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